Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 7/20 | 0.52 |
| ▸ | EPHB4 | P54760 | 9/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 2/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5723655 | 0.81 | RAB9A (0.43) | ACVRL1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL5723676 | 0.81 | AOC3 (0.49) | ACVRL1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL3275997 | 0.79 | ACVRL1 (0.48) | ACVRL1EPHB4NPC1RAB9AMEN1 | |
| SCHEMBL3539889 | 0.77 | NPC1 (0.43) | ACVRL1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL3275768 | 0.75 | DPP4 (0.46) | ACVRL1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL13633954 | 0.74 | ACVRL1 (0.42) | ACVRL1EPHB4NPC1RAB9A | |
| SCHEMBL11058830 | 0.72 | EDNRA (0.43) | NPC1RAB9AMEN1KMT2ACASP3 | |
| SCHEMBL3676870 | 0.72 | ACVRL1 (0.54) | ACVRL1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL4025660 | 0.70 | POLB (0.57) | ACVRL1NPC1RAB9APOLB | |
| SCHEMBL27192092 | 0.69 | ACVRL1 (0.36) | ACVRL1EPHB4NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1528925-B1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| US-7504408-B2 | Quinzoline derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2009-03-17 | — | — | US | disclosed |
| US-20070213367-A1 | Substituted 3-cyanoquinolines as MEK inhibitors | ASTRAZENECA AB | 2007-09-13 | — | — | US | disclosed |
| EP-1453492-B1 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2007-01-24 | — | — | EP | disclosed |
| EP-1409481-B1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-10-04 | — | — | EP | disclosed |
| US-20050250797-A1 | Quinzoline derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2005-11-10 | — | — | US | disclosed |
| EP-1450808-B1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213367-A1 | Substituted 3-cyanoquinolines as MEK inhibitors | NRAS, BRAF, MAPK1 | ACVRL1 2032/4885EPHB4 1046/4885NPC1 1623/4885 |
| US-20050250797-A1 | Quinzoline derivatives for use in the treatment of cancer | TPD52L2, NQO2, CCNI | ACVRL1 4181/4885EPHB4 4111/4885NPC1 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.